Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Reshape Lifesciences Inc (RSLS)

Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,492
  • Shares Outstanding, K 11,276
  • Annual Sales, $ 8,010 K
  • Annual Income, $ -7,130 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.59
  • Price/Sales 0.51
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.72
  • Most Recent Earnings $-1.89 on 04/04/25
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1,182.51
  • Growth Rate Est. (year over year) +184.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3000 +3.23%
on 04/09/25
3.0500 -89.85%
on 04/01/25
-0.3203 (-50.84%)
since 03/17/25
3-Month
0.3000 +3.23%
on 04/09/25
4.7186 -93.44%
on 01/21/25
-4.2103 (-93.15%)
since 01/17/25
52-Week
0.3000 +3.23%
on 04/09/25
29.0000 -98.93%
on 05/29/24
-9.2023 (-96.74%)
since 04/17/24

Most Recent Stories

More News
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 67.29 (-1.84%)
EXAS : 41.58 (-1.61%)
ABBV : 172.99 (+0.76%)
RSLS : 0.3097 (-14.71%)
ALLR : 0.9400 (+17.93%)
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

RSLS : 0.3097 (-14.71%)
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS : 0.3097 (-14.71%)

Business Summary

ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

See More

Key Turning Points

3rd Resistance Point 0.4053
2nd Resistance Point 0.3830
1st Resistance Point 0.3463
Last Price 0.3097
1st Support Level 0.2873
2nd Support Level 0.2650
3rd Support Level 0.2283

See More

52-Week High 29.0000
Fibonacci 61.8% 18.0366
Fibonacci 50% 14.6500
Fibonacci 38.2% 11.2634
Last Price 0.3097
52-Week Low 0.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar